4AA Preclinical / Limited Human
Pancragen
Synthetic pancreatic tetrapeptide bioregulator (Lys-Glu-Asp-Trp) from the Khavinson school, studied for age-related glucose dysregulation, beta-cell differentiation, and insulin resistance correction in primate and human models.
In Plain English:
Pancragen is a four-amino-acid peptide — lysine, glutamic acid, aspartic acid, tryptophan (KEDW) — synthesised by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as the defined active core distilled from polypeptide extracts of bovine pancreatic tissue. In the same tradition as Epithalon (pineal) and Cortagen (brain cortex), it represents the organ-specific bioregulator for the pancreas. At its molecular weight of 576 Da, it is small enough to cross cell and nuclear membranes and bind ACCT-rich promoter sequences, upregulating transcription factors (PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6-1, PAX4) that govern beta-cell and acinar-cell fate. In streptozotocin-diabetic rats, oral administration produced a pronounced hypoglycaemic effect and normalised endothelial adhesion. In aged female rhesus monkeys, 10-day IM dosing at 50 µg/day accelerated glucose clearance and normalised insulin and C-peptide dynamics, with partial benefit persisting three weeks post-treatment. The sole published human series (33 elderly patients with type 2 diabetes, Korkushko et al. 2011) reported significant reductions in fasting glucose, plasma insulin, and the HOMA-IR insulin-resistance index. All primary evidence originates from Khavinson's St. Petersburg group; no independent Western replication or regulatory-grade clinical trial exists.
Research Maturity
Preclinical / Limited Human (~8-12 peer-reviewed papers (2007-2021); 1 open-label human series (N=33); no independent replication+ Studies)
Focus
Metabolic Health
Pancreatic Support
Origin
Synthesised by V.K. Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology (Russia) via directed amino-acid synthesis based on compositional analysis of polypeptide fractions extracted from bovine pancreatic tissue. Classifed as a Cytogen (synthetic peptide bioregulator), commercially distributed under the trade name Pancragen® by TD Peptid Bio (St. Petersburg). The parent polypeptide extract — Pancramin® — has been in clinical use in Russian medicine since the 1980s; Pancragen is the defined synthetic descendant introduced circa 2007 (first PubMed-indexed study PMID 18642713). The amidated analogue H-Lys-Glu-Asp-Trp-NH₂ was also studied (PMID 21246099) and shows comparable activity.
Mechanism
Penetrates cell and nuclear membranes by virtue of low molecular weight (576 Da) and binds ACCT dinucleotide motifs in the major groove of DNA in promoter regions of pancreatic developmental genes. Upregulates a constellation of transcription factors governing both endocrine and exocrine pancreatic lineages: PDX1 and PTF1A for acinar progenitor specification; PDX1, PAX6, PAX4, FOXA2, NKX2-2, NKX6-1, and NGN3 for islet endocrine commitment and beta-cell maturation. Net result is stimulation of acinar and islet-of-Langerhans cell differentiation, reversing the age-related loss of differentiation-marker expression observed in aged pancreatic cell cultures. Anti-apoptotic effects are documented: reduces proapoptotic p53 and caspase-3 expression, elevates antiapoptotic MCL1, decreases cathepsin B activity. Anti-inflammatory arm: suppresses TNF-α, elevates IGF-I. In microvascular studies, intramuscular dosing normalised adhesion properties of mesenteric capillary endothelium in streptozotocin-diabetic rats without affecting capillary permeability, consistent with an endothelioprotective mechanism.
Outcome
Blood glucose (↓, oral in streptozotocin-diabetic rats, PMID 18642713); mesenteric capillary endothelial adhesion (normalised, IM, same model); glucose disappearance rate after IV glucose load (↑, aged rhesus monkeys, PMID 25946840); plasma insulin and C-peptide dynamics (normalised, same model); glucose tolerance (restored toward young-animal pattern, PMID 28509500, vs glimepiride control); expression of acinar markers Pdx1 and Ptf1a, and islet markers Pdx1/Pax6/Pax4/Foxa2/Nkx2.2 in aged pancreatic cell cultures (↑, PMID 23486591); fasting glucose (↓), plasma insulin (↓), HOMA-IR insulin resistance index (↓) in 33 elderly type 2 diabetic patients (PMID 22448364); caspase-3 and cathepsin B activity (↓); TNF-α (↓); IGF-I (↑); MMP2/MMP9 (↑, remodelling); apoptosis markers in streptozotocin model (PMID 21246099).
